Evidence map›Paper›PMID 31685964›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations.

Jennifer Pors, Julia Naso, Kyra Berg, Andrew Churg

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jennifer PorsDepartment of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.
Julia NasoDepartment of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.
Kyra BergDepartment of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.
Andrew ChurgDepartment of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada. achurg@mail.ubc.ca.
University of British Columbia · CAVancouver General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The separation of benign from malignant mesothelial proliferations is a morphologically difficult problem. Mutations/deletions of components of the Hippo pathway are frequent in malignant mesotheliomas, and one downstream effect of aberrant Hippo signaling is increased production of cyclin D1. We examined expression of cyclin D1 nuclear staining in two tissue microarrays containing 52 reactive epithelial mesothelial proliferations, 51 reactive spindle cell mesothelial proliferations, 54 epithelial mesotheliomas, and 22 sarcomatous/desmoplastic mesotheliomas. When present, cyclin D1 staining was always strong, hence the arrays were scored as 0, 1-25%, 26-50%, 51-75%, and 76-100% staining. Both arrays showed a similar pattern. Reactive epithelial proliferations generally showed no staining (42/52 cases) or 1-25% staining (10/52 cases) with no cases showing >25% staining. Overall for reactive epithelial proliferations the maximum staining was 14.8% and mean 1.1 ± 2.9%. For epithelial mesotheliomas 39/54 (72%) cases demonstrated >25% staining, with 8/54 in the 26-50% staining range, 9/54 in the 51-75% range, and 22/54 in the >75% range. Combinations of staining using cyclin D1 >50% plus BAP1 or MTAP loss in epithelial mesotheliomas produced about a 10% increase in sensitivity. Reactive spindle cell proliferations showed a broader range of staining with 27/51 in the 1-25% range, 5/51 in the 26-50% range, and 1/51 >50%. Eleven of 22 sarcomatous/desmoplastic mesotheliomas scored 50% or greater. We conclude that for epithelial mesothelial proliferations, the finding of >50% of tumor cells staining supports a diagnosis of epithelial mesothelioma with 100% specificity but only modest (57%) sensitivity.

Indexed as

Cell ProliferationImmunohistochemistryBiomarkers, TumorCyclin D1Diagnosis, DifferentialEpithelial CellsHumansMesothelioma, MalignantPleural NeoplasmsPredictive Value of TestsPurine-Nucleoside PhosphorylaseReproducibility of ResultsRetrospective StudiesTissue Array AnalysisTumor Suppressor ProteinsUbiquitin Thiolesterase5'-methylthioadenosine phosphorylaseBAP1 protein, humanBiomarkers, TumorCCND1 protein, humanCyclin D1Purine-Nucleoside PhosphorylaseTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID31685964
OpenAlexW2987044308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.